Published 29th May, 2026
For many years, follicular lymphoma (FL) has been described as treatable but not curable. Patients often experience long periods of remission, but with the expectation that the disease may eventually return.
New long-term data are starting to challenge that assumption, and that shift matters. If a proportion of patients can achieve outcomes consistent with cure, it raises important questions not only about how FL behaves, but also about how treatment strategies, follow-up, and research priorities should evolve.
To explore what this means in practice, the FLF’s Chief Medical Officer Dr Mitchell Smith interviewed the senior investigator of the study, Dr Jonathan Friedberg, to examine both the promise and the limitations of these findings. Alongside this, an FLF patient representative helped to shape the questions and shared reflections from a patient perspective – ensuring the discussion captures lived experience as well as scientific insight.
At the FLF, this question sits at the heart of our research strategy. We are focused on understanding which patients achieve long-term remission, why this happens, and how those outcomes can be extended to more people. Studies like this provide critical signals, but they also highlight the gaps that remain, from identifying predictive markers to improving treatment approaches. Another crucial gap for patients living with FL is that clinicians still have no reliable way to reassure a patient that they are in this more favourable group, so the findings do little to reduce the anxiety many people feel about relapse.
This is an important moment. It signals that follicular lymphoma may not be as uniformly lifelong as once thought, and that with the right investment in research, the possibility of durable remission, or even cure, could become more predictable, more achievable, and accessible to more patients.
The study comes from a clinical trial that began in 2001, involving patients with advanced-stage FL treated with CHOP chemotherapy in combination with a CD-19 antibody-based treatment. Patients were randomised to receive either CHOP followed by rituximab (which is still widely used today), or CHOP followed by radioimmunotherapy (CHOP-RIT) – which is now rarely used in clinical practice.
Researchers analysed outcomes after more than 15 years of follow-up and applied a statistical method termed “cure modelling”. This approach estimates whether a proportion of patients are unlikely to relapse, based on how their long-term outcomes compare with the general population.
The key finding is that around 35% of patients treated with R‑CHOP may be “cured”, meaning their lymphoma did not return during long-term follow-up. The trial also found that patients in the CHOP-RIT arm had better 15-year progression-free survival than those treated with R‑CHOP (47% vs 34%), while the study also showed that most relapses occur within the first decade after treatment, with new relapses becoming uncommon after 10 years.
However, there are important caveats. The results relate to a specific treatment approach, and late relapses can still occur, even after many years. Although CHOP-RIT performed better than R‑CHOP for long-term progression-free survival in this trial, radioimmunotherapy of this kind is now rarely used in routine practice. In addition, it is not yet possible to predict which individual patients will fall into the “cured” group.
These findings suggest that outcomes for some patients may be more favourable than previously recognised, but they do not redefine FL as universally curable.
In conversation with FLF, Prof Friedberg described these findings as a potential shift in how FL is understood, but emphasized that caution is essential.
“What we showed was that… about 35% of patients treated with R‑CHOP were cured… and events after 10 years are very rare.”
He noted that long-term remission in FL is not a new observation. Clinicians have long seen patients doing well many years after treatment. What is new is the strength of long-term follow-up data and the use of modelling to frame these outcomes more explicitly.
The discussion also highlighted an important question about how the term “cure” is used in medicine. In other lymphomas, rare late relapses do not prevent a disease from being considered curable. In FL, however, the long-standing expectation of recurrence has shaped more cautious language.
Dr Mitchell Smith, FLF’s Chief Medical Officer, reflected on the balance needed when discussing these results:
Crucially, the study does not provide certainty at the individual level. “Cure” here reflects probability, not guarantee; individual patients cannot yet be identified as cured; and ongoing follow-up remains essential.
For patients, the idea of cure is both powerful and complex.
FL patient and advocate Robert McEachern, who is part of the FLF’s patient involvement group the Super Supporters and who contributed to this commentary article, reflects on the shift in thinking:
He also captures the emotional reality of living with long-term uncertainty:
This perspective brings an important depth to the discussion. While new evidence may offer reassurance, it can also challenge years, or decades, of being told that FL will eventually return. Changing that mindset is not immediate, and for many people, it will take time.
His reflections also raise an important scientific point: long-term remission is not unique to a single treatment approach, and similar patterns may emerge across different therapies as more long-term data become available.
This is where careful interpretation matters.
In everyday language, cure implies complete and permanent elimination of disease. In clinical practice, it is often used to describe a situation where the risk of relapse becomes very low.
In FL, late relapses can still occur, although they are uncommon. These events may reflect new biological processes rather than the original disease, and there are currently no reliable tools to identify who is cured.
As a result, many experts see cure in FL as a population-level concept, meaning it describes what happens across large groups of patients over time, rather than something doctors can yet say for certain about one individual person.
For patients:
For clinicians:
For research:
This research represents what some describe as a shift in how follicular lymphoma is understood.
But such shifts are gradual. They require time, evidence, and open conversations between patients and healthcare teams.
As Robert McEachern reflects:
At FLF, our role is to support that process, ensuring that discussions about “cure” are balanced, evidence-based, and grounded in patient experience.
This article is intended for educational and disease awareness purposes only and the information presented and discussed does not constitute medical advice. Please consult with your healthcare provider for medical advice.
